Home

Richard Chin

CIK 1337252 · Chief Executive Officer · last filed 2026-08-20

Richard Chin is a Chief Executive Officer who has filed 60 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for CTKB, was dated Aug 20, 2026. Across all open-market trades the lifetime net is −$7.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $131.4K across reported positions. 18 SEC filings were submitted jointly with Galena Biopharma, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$131.4K

Companies

6

Total Filings

60

Lifetime Open-Market Net

-$7.11M

Filer Profile

Reported Address
C/O OXIGENE, INC.
230 THIRD AVENUE
WALTHAM, MA 02451
Related Filers
Galena Biopharma, Inc. — 18 joint filings, latest 2017-10-10
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CTKB Director 28,499 $4.61 $131.4K $0 7 2026-08-20
Kindred Biosciences, Inc. (KIN) Delisted Chief Executive Officer 0 $9.25 $0 -$5.88M 32 2021-08-30
SELLAS Life Sciences Group, Inc. (GALE) Delisted Director 1,045 — — -$1.23M 11 2017-10-10
ImmunoCellular Therapeutics, Ltd. (IMUC) Delisted Director — — — $0 2 2013-09-24
SELLAS Life Sciences Group, Inc. (RXII) Delisted Director — — — $0 6 2011-09-29
Oncotelic Therapeutics, Inc. (OXGN) Delisted President and CEO 19,604 — — $0 2 2008-01-15

Recent Filings

60 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-20 CTKB Exer (M) +6,107 $0 EDGAR
2026-06-12 CTKB Grant (A) — $0 EDGAR
2026-05-20 CTKB Exer (M) +6,107 $0 EDGAR
2026-03-12 CTKB Exer (M) +6,107 $0 EDGAR
2025-11-20 CTKB Exer (M) +6,107 $0 EDGAR
2025-08-20 CTKB Exer (M) +4,071 $0 EDGAR
2025-06-20 CTKB Grant (A) — $0 EDGAR
2021-08-30 Kindred Biosciences, Inc. (KIN) Delisted Disp (D) −1,713,271 -$15.85M EDGAR
2021-08-04 Kindred Biosciences, Inc. (KIN) Delisted Mixed −360,000 -$368.2K EDGAR
2021-07-07 Kindred Biosciences, Inc. (KIN) Delisted Sell (S) −40,000 -$367.1K EDGAR
Showing 1–10 of 60
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.